Lilly's phase 3 program evaluates efficacy and safety in obesity and overweight, type 2 diabetes, obstructive sleep apnea, knee osteoarthritis pain, cardiovascular and renal outcomes, chronic low back pain, and metabolic liver disease [1]
A federal recommendation should never be interpreted as a personal treatment recommendation
wonderful company to work with Ive been using VitaStir for several months for the semiglutide injections at home and have had a wonderful experience
However, the exact number depends on factors like skin tone, pigmentation depth, and body response
What I did find interesting is over time, when you first had these drugs approved in 2015 through the end of 2024, there was an increase in the use and by 2024, what we are seeing is people being prescribed these medications who don't have the indication for it
Fatigue and energy management Some users experience fatigue on tirzepatide , especially at higher doses or after recent dose escalations